Drug product release method, formulation

Our formulation development activities we developed both a biorelevant dissolution method, and a drug product release method. At this point in development, all of our formulation development activities are complete, making the biorelevant method less important. The formulation(s) is fixed, and we are now concerned with demonstrating that we can consistently manufacture batches of drug product. We will also want to show that the release characteristics of the dosage unit do not change on stability. Oiu" drug product release method will fulfill this role and will be the primary dissolution method, until the method conditions need to be revisited when in vivo data become available from om first clinical studies. At that time, the method should be revisited to evaluate how biorelevant our in vitro data are. 

An analytical method is a laboratory procedure that measures an attribute of a raw material, drug substance, or a drug product. Analytical method validation is the process of demonstrating that an analytical method is reliable and adequate for its intended purpose. Any method that is utilized to determine results during drug substance and formulation development will have to be validated. Reliable data for release of clinical supplies, stability, and setting shelf life can only be generated with appropriate validated methods. 

Prior to developing a drug product, a number of experiments need to be conducted that will fully characterize the API. This information will then be used to help guide formulation development efforts. Each of the critical pieces of information that are needed for formulation development will be discussed below. These include a screening process where an ideal soHd-state salt form is selected and the generation of a suite of analytical methods necessary to probe the critical quality attributes of the new chemical entity, to support synthetic optimization scale-up, stability studies, and the release of material for GLP and experimental use. 

---